Additional work by Gunderson et al. demonstrates the immunomodulatory capacity of ibrutinib in myeloid cells and the ability of BTK inhibition to promote an increased CD8+ T cell immune response in pancreatic ductal adenocarcinoma (PDAC) (42). This evidence concerns the gene CD8A and pancreatic ductal adenocarcinoma.